TRED-HF

Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomized trial - The Lancet - 2019

Brief Summary:

Patients with dilated cardiomyopathy whose function recovers with treatment are at increased risk of relapse at 6 months if treatment is withdrawn.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/30429050